Efficacy and Safety Study of Seroquel SR in the treatment of Major Depressive Disorder
Study identifier:D1448C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients with Major Depressive Disorder
Medical condition
Major depressive disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine
Sex
All
Actual Enrollment
338
Study type
Interventional
Age
66 Years +
Date
Study Start Date: 01 Sept 2006
Primary Completion Date: 01 Dec 2007
Study Completion Date: 01 Dec 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Catherine Datto
AstraZeneca
